India’s First MRNA-Based Covid Vaccine Gets DCGI Approval For Phase 2-3 Trials

New Delhi: India’s first mRNA-based Covid-19 vaccine on Tuesday got the Drugs Controller General of India (DCGI) nod to move into Phase 2 and 3 trials. According to reports, the Centre informed that the vaccine developed by Gennova Biopharmaceuticals Ltd. was found to be safe, and was given go-ahead for Phase II/III trials.┬áThe Pune-based biotechnology… Continue reading India’s First MRNA-Based Covid Vaccine Gets DCGI Approval For Phase 2-3 Trials